Inhibition of transforming growth factor-β1 gene overexpression as a strategy to prevent fibrosis

Contributions to Nephrology

Volumn 131, Issue , 2001, Pages 107-113

  Gambaro, Giovanni ^a   Weigert, Cora ^b   Ceol, Monica ^a,b   Schleicher, Erwin D ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARRIER PROTEIN; DIALYSIS FLUID; GLUCOSE; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOENZYME; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; SCLEROPROTEIN; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BIOSYNTHESIS; CHEMICAL PHENOMENA; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVATION; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MESANGIUM; METABOLISM; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; REVIEW; TIME;

ANIMALS; CARRIER PROTEINS; DEPRESSION, CHEMICAL; DIABETIC NEPHROPATHIES; DIALYSIS SOLUTIONS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GENE EXPRESSION REGULATION; GLOMERULAR MESANGIUM; GLUCOSE; GLYCOSAMINOGLYCANS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LATENT TGF-BETA BINDING PROTEINS; NF-KAPPA B; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PERITONITIS; PROTEIN KINASE C; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035526693     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (36)

1. Border WA, Ruoslahti E: Transforming growth factor-β: The dark side of tissue repair. J Clin Invest 1992;90:1-7.
2. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
3. Pollok CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JE, Sheil AG: Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989;9:198-204.
4. Fieren M, van den Bernd G, Bonta IL: Endotoxin-stimulated peritoneal macrophages obtained from CAPD patients show increased capacity to release interleukin-1β in vitro during peritonitis. Eur J Clin Invest 1990;20:453-457.
5. 1 of human peritoneal mesothelial cells: Effect of cytokine co-stimulation. Peril Dial Int 1999;19:221-230.
6. 3 in surgically induced pelvic adhesion in the rat. Obstet Gynecol 1994;83:449-454.
7. Lai KN, Szeto CC, Lam CWK, Leung JCK: Growth factors in continuous ambulatory peritoneal dialysis effluent. Am J Nephrol 1999;19:416-422.
8. 1 and basic fibroblast growth factor in patients on CAPD: A study during non-infected steady state and peritonitis. Inflammation 1999;23:131-139.
9. 1 in peritoneal dialysis. J Lab Clin Med 1999;134:124-132.
10. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factoř. Nature 1990;346:371-373.
11. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
12. Border WA: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
13. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-423.
14. 1 (latency-associated peptide) inhibits active transforming growth factor in transgenic mice. Proc Natl Acad Sci USA 1996;93:5877-5882.
15. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E: Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-475.
16. 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-155.
17. Kashihara N, Maeshina Y, Makino H: Therapeutic intervention in glomerulonephritis by oligonucleotides. Exp Nephrol 1997;5:126-131.
18. 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-777.
19. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
20. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404-411.
21. Clarkson MR, Gupta S, Murphy M, Martin V, Godson C, Brady HR: Connective tissue growth factor: A potential stimulus for glomerulosclerosis and tubulointerstitial fibrosis in progressive renal disease. Curr Opin Nephrol Hypertens 1999;8:543-548.
22. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF: Dual role for the latent transforming growth factor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995;131:539-545.
23. Flaumenhaft R, Kojima S, Abe M, Rifkin DB: Activation of latent transforming growth factor-β. Adv Pharmacol 1993;24:51-76.
24. Hori Y, Katoh T, Hirakata M, Joki N, Kaname S, Fukagawa M, Okuda T, Ohashi H, Fujita T, Miyazono K, Kurokawa K: Anti-latent TGF-β binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int 1998;53:1616-1625.
25. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992;42:285-291.
26. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, Baggio B: Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46:797-806.
27. 1 overexpression and pathological changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000, in press.
28. Hagège J, Delarue F, Peraldi MN, Sraer JD, Rondeau E: Heparin selectivity inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells. Lab Invest 1994;71:828-837.
29. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
30. 1 gene expression by glucose in mesangial cells (abstract). Diabetologia 1999;42(suppl 1):A272.
31. Schleicher E, Nerlich A: The role of hyperglycemia in the development of diabetic complications. Horm Metabol Res 1996;28:367-373.
32. Higuchi C, Nihei H: The role of protein kinase C activity in the proliferation of peritoneal fibroblasts. Perit Dial Int 1999;19(suppl 2):353-357.
33. 1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989;264:19373-19378.
34. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL: Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncoprotein-mediated transcription. J Cell Biol 1991;116:31-42.
35. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, Gambaro G: Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999;33:105-110.
36. Bazzato G, Fracasso A, Gambaro G, Baggio B: Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995;346:740:741.